{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:46:01Z","timestamp":1784940361362,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.lungcan.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T15:01:51Z","timestamp":1489849311000},"page":"145-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Targeting BAP1: a new paradigm for mesothelioma"],"prefix":"10.1016","volume":"109","author":[{"given":"L.M.","family":"Schunselaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2017.03.005_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0003-4975(10)60182-8","article-title":"Pleural mesothelioma","volume":"43","author":"Martini","year":"1987","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.lungcan.2017.03.005_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2486\/indhealth.39.183","article-title":"Pathology of human malignant mesothelioma \u2013 preliminary analysis of 1,517 mesothelioma cases","volume":"39","author":"Suzuki","year":"2001","journal-title":"Ind. Health"},{"issue":"6","key":"10.1016\/j.lungcan.2017.03.005_bib0015","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.lungcan.2017.03.005_bib0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: new insights into a rare disease","volume":"39","author":"Remon","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.lungcan.2017.03.005_bib0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.lungcan.2017.03.005_bib0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2017.03.005_bib0035","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol. Cell. Biol."},{"issue":"7295","key":"10.1016\/j.lungcan.2017.03.005_bib0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.lungcan.2017.03.005_bib0045","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.lungcan.2017.03.005_bib0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2017.03.005_bib0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.lungcan.2017.03.005_bib0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gene.2015.03.031","article-title":"Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma","volume":"563","author":"Sneddon","year":"2015","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.lungcan.2017.03.005_bib0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.lungcan.2017.03.005_bib0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/pin.12453","article-title":"BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests","volume":"66","author":"Hida","year":"2016","journal-title":"Pathol. Int."},{"issue":"10","key":"10.1016\/j.lungcan.2017.03.005_bib0075","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2017.03.005_bib0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2017.03.005_bib0085","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2017.03.005_bib0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2017.03.005_bib0095","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2017.03.005_bib0100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.lungcan.2017.03.005_bib0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12013-011-9184-6","article-title":"An emerging model for BAP1's role in regulating cell cycle progression","volume":"60","author":"Eletr","year":"2011","journal-title":"Cell Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.lungcan.2017.03.005_bib0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.lungcan.2017.03.005_bib0115","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4161\/cc.9.13.12147","article-title":"The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors","volume":"9","author":"Bommi","year":"2010","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.lungcan.2017.03.005_bib0120","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lungcan.2017.03.005_bib0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2017.03.005_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-11-0962","article-title":"Polycomb repressor complex-2 is a novel target for mesothelioma therapy","volume":"18","author":"Kemp","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2017.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med."},{"issue":"2","key":"10.1016\/j.lungcan.2017.03.005_bib0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2017.03.005_bib0145","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"issue":"49","key":"10.1016\/j.lungcan.2017.03.005_bib0150","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.lungcan.2017.03.005_bib0155","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol. Cell. Biol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217302593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:28:46Z","timestamp":1535959726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217302593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":31,"alternative-id":["S0169500217302593"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.03.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BAP1: a new paradigm for mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}